Bafna Pharmaceuticals, engaged in the business of manufacturing of formulations of Non Betalactam products, has formally inaugurated its Formulation Research and Development facility, a pilot plant in Chennai to facilitate the development of pharma formulations and to cater to the needs of the global customers. The facility was inaugurated by Mike Nithavrianakis, British Deputy High Commissioner to Southern India. This facility is spread across 5000 sq. feet for formulation and analytical development as per international standards. It is in complete compliance with cGMP, eGLP & ICII guidelines in conducting the R&D activities along with full regulatory compliance to EU-DMF and US-DMF.

Talking on this occasion, Bafna Mahaveer Chand, chairman and managing director, said, “Bafna Pharmaceuticals' investment in the R&D facility reinforces our vision to become the leading professionally run global pharma company setting standards across the pharma value.”

With advanced R&D equipments, testing instruments and process control facilities, the R&D center is equipped to manufacture new products from laboratory scale to validation batches. The R&D center has qualified and competent research scientists,who have developed many innovations in the manufacture of formulations, to meet the various requirements of the global market. We strongly believe that with the launch of the new R&D centre we will significantly elevate our efforts in enhancing and developing new products and exceed our customer expectations, he added.

This facility will offer a one stop solution right from development to formulation to dossier making to commercial production and in the long-run, the facility is going to be a completely independent profit making center. The overall objective of this facility is to develop the pharmaceutical products on contract basis and to design and develop the products indigenously for the ever expanding pharma market. This facility will propel to the realization of our mission of achieving Rs 500 crore by 2013.